PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Clinical trials for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) explained in plain language.
Never miss a new study
Get alerted when new PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS) trials appear
Sign up with your email to follow new studies for PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare overgrowth conditions
Disease control Recruiting nowThis study tests a new drug called CYH33 in people with rare conditions that cause abnormal tissue growth and blood vessel malformations (PROS and PRVM). The trial has two phases: phase I finds the safest dose, and phase II checks if the drug shrinks growths. About 141 adults and…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE1, PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for rare overgrowth disorder: daily pill could tame symptoms
Disease control Recruiting nowThis study tests a daily oral drug called alpelisib in people aged 2 and older with PIK3CA-related overgrowth spectrum (PROS), a rare condition causing abnormal tissue growth. The goal is to see if the drug can shrink overgrown tissue and improve symptoms. About 104 participants …
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Last-Resort drug alpelisib made available for patients with no other options
Disease control AVAILABLEThis program provides access to the drug alpelisib (BYL719) for patients with PIK3CA-related overgrowth spectrum or breast cancer who have no other treatment options and cannot join a clinical trial. It is not a study but a way for doctors to request the drug for individual patie…
Matched conditions: PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC